Article title: The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations
Authors: Reinaldo Acevedo, Xilian Bai, Ray Borrow, Dominique A. Caugant, Josefina Carlos, Mehmet Ceyhan, Hannah Christensen, Yanet Climent, Philippe De Wals, Ener Cagri Dinleyici, Gabriela Echaniz-Aviles, Ahmed Hakawi, Hajime Kamiya, Andromachi Karachaliou, Jay Lucidarme, Susan Meiring, Konstantin Mironov, Marco A. P. Sáfadi, Zhujun Shao, Vinny Smith, Robert Steffen, Bianca Stenmark, Muhamed-Kheir Taha, Caroline Trotter, Julio A. Vázquez & Bingqing Zhu
Journal: Expert Review of Vaccines
Bibliometrics: Volume 18, Issue 1, pages 15-30
DOI: 10.1080/14760584.2019.1557520
This article was originally published with an incomplete conflict of interest statement. This has been updated in the online version and the statement can also be found below:
R. Borrow, J. Lucidarme and X. Bai perform contract work for Public Health England on behalf of GSK, PATH, Sanofi Pasteur and Pfizer. M.K. Taha performs contract work for the Institut Pasteur funded by GSK, Pfizer and Sanofi Pasteur. M.K. Taha has a patent NZ630133A Patent with GSK “Vaccines for serogroup X meningococcus” issued. S. Meiring has received grant funding for a meningococcal carriage study by Sanofi Pasteur. G. Enchaniz-Aviles has received support for research projects from GSK and Pfizer. J.A. Vázquez performs contract work for the Carlos III Health Institute, funded by GSK and Pfizer, and has received personal fees from Sanofi Pasteur outside the submitted work. P. De Wals has received research grants, and reimbursements of travel expenses from vaccine manufacturers including GSK, Novartis, Sanofi Pasteur, and Pfizer, as well as from governmental agencies including the Quebec Ministry of Health and Social Services, Health Canada, and the Public Health Agency of Canada. M.A.P. Sáfadi has received grants to support research projects and consultancy fees from GSK, Pfizer and Sanofi Pasteur. C. Trotter has received consulting fees from GSK and an honorarium from Sanofi-Pasteur for developing and delivering a modeling workshop at a previous GMI meeting. H. Christensen has received reimbursements of travel expenses and, for previous GMI meetings, honoraria, from Sanofi-Pasteur; consultancy fees from IMS Health and AstraZeneca; honoraria from GSK, paid to her employer. She is supported by the NIHR Health Protection Research Unit in Evaluation of Interventions at the University of Bristol. V. Smith reports grants from Sanofi Pasteur, GSK, and Pfizer, for representing Meningitis Research Foundation outside the submitted work. M. Ceyhan received personal fees and non-financial support from Pfizer, Turkey during the conduct of the study; and project support from MSD and GSK INC outside the submitted work. E. C. Dinleyici reports contract work for the Eskisehir Osmangazi University funded by GSK, Sanofi Pasteur, and Pfizer, outside the submitted work. D. Caugant has nothing to disclose. Relating to vaccine producers, R. Steffen has received a grant from Pfizer and personal fees from GSK, Foundation Merieux, ParVx (now Emergent Biosolutions), Sanofi Pasteur, Takeda, and Valneva.
The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.